OR WAIT null SECS
January 09, 2026
Video
Rubin discusses the recently released best practice recommendations for HypoPT treatment, explaining how clinicians can help turn this dangerous disease around.
January 08, 2026
Rubin discusses an analysis of Ascendis’s program for patients who had received PTH treatment but weren’t eligible for clinical trials of palopegteriparatide.
November 04, 2025
Article
Based on results from the THRIVE and THRIVE-2 phase 3 studies, this Biologics License Application includes a request for Priority Review.
September 22, 2025
A significant amount of TED cases go undiagnosed due to a lack of routine screening – Khachikian discusses what is needed to address this problem.
July 14, 2025
Already approved by the FDA based on data from the first half of the PaTHway trial, 3-year extended results have indicated lasting efficacy.
May 06, 2025
Our April 2025 month in review highlights significant advancements in endocrinology, including innovative therapies and FDA approvals that enhance diabetes management.
March 13, 2025
Chronic hypoparathyroidism requires holistic management addressing more than just calcium normalization to achieve optimal patient outcomes.
August 12, 2024
Palopegteriparatide’s approval was based on positive data from the global Phase 2 PaTH Forward and Phase 3 PaTHway trials.
June 04, 2024
Our endocrinology month in review for May 2024 highlights pipeline news in endocrinology and spotlights our coverage of the landmark FLOW trial from ERA 2024.
May 14, 2024
The FDA has extended the review period for palopegteriparatide in treatment of hyperparathyroidism in adult patients by 3 months to August 14, 2024.
